LAVAL, Quebec , Sept. 2, 2015 /CNW/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its affiliate has entered into a definitive agreement under which Valeant will acquire Synergetics USA, Inc. (SURG) for $6.50 per share in cash. In addition to the upfront cash payment, Synergetics stockholders will receive additional […]

Incyte to pay Hengrui $25 million upfront plus the potential for milestone and royalty payments   WILMINGTON, Del.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq: INCY) today announced a global license and collaboration agreement with Jiangsu Hengrui Medicine Co., Ltd. for the development and commercialization of SHR-1210, an investigational anti-PD-1 monoclonal antibody. Under the agreement, Incyte will have the […]

NORWALK, Conn. & BURLINGTON, Mass.–(BUSINESS WIRE)–Xerox (NYSE:XRX) and inVentiv Health today announced Xerox’s acquisition of inVentiv Patient Access Solutions (iPAS), an inVentiv Health company. The acquisition will expand Xerox’s pharmacy solutions portfolio with an offering to help pharmaceutical companies drive product adoption and support patients in minimizing or eliminating financial and reimbursement hurdles. iPAS serves […]

San Francisco-based Audentes Therapeutics, announced today that it will buy Cardiogen Sciences, Inc., headquartered in Palo Alto, Calif. Financial details were not disclosed.   Audentes focuses on developing and commercializing adeno-associated virus (AAV) gene therapies for rare diseases. It currently has three products in development, AT001 for X-Linked Myotubular Myopathy (XLMTM), AT002 for Pompe disease, […]

Drugmaker Bristol-Myers Squibb said it bought rights to a mid-stage fibrosis drug and its privately held developer for up to $1.25 billion, boosting its pipeline for drugs that treat tissue scarring. The deal gives Bristol-Myers access to Promedior Inc’s lead experimental drug, PRM-151, which is being tested to treat two types of fibrosis. PRM-151 is […]

CRANBURY, N.J. – Amicus Therapeutics, Inc. (FOLD) inked a deal to acquire the privately-held biopharmaceutical company Scioderm Inc., Inc. in a deal worth up to $847 million, the company announced this morning.   The acquisition places Scioderm’s lead product candidate Zorblisa, a topical cream for the treatment of Epidermolysis Bullosa (EB) into Amicus’ rare and […]

Novo Nordisk (NVO), headquartered in Copenhagen, Denmark, announced yesterday that it will buy Calibrium LLC and MB2 LLC, two private biopharma companies based in Indiana.   Calibrium, located in Carmel, Ind., focuses on developing drug candidates for diabetes and related metabolic diseases. It was co-founded by Fritz French, the company’s chief executive officer, and Richard […]

MUMBAI: As Israeli drugmaker Teva readies to acquire Allergan as part of its recent $40.5-billion deal, a large bounty of products is expected to be up for grabs for generic drugmakers. According to collated data, products worth nearly $600 million may be needed to be divested as part of the anti-trust regulations of the US […]

Sucampo Launches Tender Offer to Acquire R-Tech Ueno Acquisition Expected to be Immediately Accretive Advances Sucampo Strategy to Strengthen Financial Performance and Diversify Pipeline Acquisition Expected to Close in Q4 2015 Company to Host Conference Call Today at 8:00 a.m. EDT   BETHESDA, Md., Aug. 26, 2015 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today […]

Medtronic To Acquire Twelve, Developer Of Transcatheter Mitral Valve Replacement Device DUBLIN – August 25, 2015 – In support of the company’s therapy innovation strategy, Medtronic plc (NYSE: MDT) today announced that it has signed a definitive agreement to acquire Twelve, Inc. (“Twelve”), a privately-held medical device company based in Redwood City, Calif., focused on […]